Ultragenyx Pharmaceutical Inc

RARE remains in a Stage 2 advancing regime with a bullish medium-term bias underpinned by clear higher-high/higher-low structure and rising EMAs. However, the active Bullish Exhaustion pattern at the July highs and overbought conditions signal waning momentum. Price is currently pulling back into the 9/21 EMA zone, and short-term execution is neutral until this pullback is absorbed. We defer entry and look for acceptance above the EMAs before engaging.

• ↑Q1 2026 revenue up 28% YoY to $136M, driven by Crysvita sales.
• ↑2026 revenue guidance raised to $730–760M, reflecting 8–13% growth.
• ↓Q1 2026 net loss $185M, operations cash burn $197M stresses liquidity.